Nyxoah SA
No enriched coverage for $NYXH in the last 7 days.
No SEC Form 4 filings for $NYXH in the last 30 days.
See all $NYXH insider activity →Nyxoah S.A. (NYXH) reported a wider Q2 GAAP loss of EUR32.96 million, or EUR0.578 per share, versus a EUR20.61 million loss and EUR0.551 per share a year earlier. Revenue increased 473.1% to EUR7.68 million from EUR1.34 million, according to the company.
Nyxoah SA (NYXH) reported Q2 2026 net revenue of €7.7 million, up from €1.3 million a year earlier, with U.S. net revenue €5.2 million, 22% higher sequentially. First-half 2026 net revenue was €14.0 million. The company secured $110 million financing, had €97.8 million cash at June 30, and guided FY2026 revenue €36-40 million and gross margin 60-62%.
Nyxoah SA said its Genio U.S. launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients in prior authorization. It reported early launched accounts reached 15% market share in six months and said reimbursement is stable, with CMS code changes not affecting coverage and prior authorization approvals at a 100% rate. Nyxoah reiterated 2026 revenue guidance of EUR 36m to EUR 40m and noted a preliminary cash balance of EUR 98m.
Recent NYXH coverage spans financial news, earnings and market movers.
Wider loss despite sharp revenue growth suggests margin pressure and potential cash-burn risk, likely keeping valuation and financing expectations in focus.
The release combines accelerating U.S. commercialization metrics with a cash boost and maintained full-year revenue and margin targets, supporting a constructive near-term risk view.
Launch traction metrics and reimbursement stability support the bull case for adoption and payer acceptance, with a potential label update catalyst in early 2027.
Preliminary revenue and U.S. commercial metrics plus CMS-proposed reimbursement increases are near-term catalysts for NYXH’s U.S. ramp narrative.
This is a large-holder position update (10%+ voting rights) that can affect control dynamics and near-term sentiment, but it is not an operating or financial catalyst.
alphai scores every news story that mentions NYXH with an AI model for sentiment and relevance, and aggregates insider trades from Nyxoah SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
Nyxoah S.A. (NYXH) reported a wider Q2 GAAP loss of EUR32.96 million, or EUR0.578 per share, versus a EUR20.61 million loss and EUR0.551 per share a year earlier. Revenue increased 473.1% to EUR7.68 million from EUR1.34 million, according to the company.
2 min readNyxoah SA (NYXH) reported Q2 2026 net revenue of €7.7 million, up from €1.3 million a year earlier, with U.S. net revenue €5.2 million, 22% higher sequentially. First-half 2026 net revenue was €14.0 million. The company secured $110 million financing, had €97.8 million cash at June 30, and guided FY2026 revenue €36-40 million and gross margin 60-62%.
6 min readNyxoah SA said its Genio U.S. launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients in prior authorization. It reported early launched accounts reached 15% market share in six months and said reimbursement is stable, with CMS code changes not affecting coverage and prior authorization approvals at a 100% rate. Nyxoah reiterated 2026 revenue guidance of EUR 36m to EUR 40m and noted a preliminary cash balance of EUR 98m.
4 min readNyxoah SA (Euronext Brussels/Nasdaq: NYXH) reported preliminary, unaudited Q2 2026 results: global net revenue expected at ~€7.7m (+21% sequential) and U.S. net revenue ~€5.2m (+22%). U.S. metrics included 55 surgeons trained and 89 new accounts activated. CMS proposed 12% hospital and 15% ASC reimbursement increases for Genio. Cash/assets expected ~€97.8m; €36m–€40m full-year guidance.
6 min readNyxoah SA (Euronext Brussels/Nasdaq: NYXH) said it received EU transparency notifications. Orin Hirchman-controlled entities acquired voting securities, raising voting rights to 14,534,880 (14.55%) vs a 10% threshold, effective June 10, 2026. Resmed Inc. reported a passive downward crossing below 3%, holding 1,943,828 voting rights (1.95%).
3 min readNyxoah SA said it completed a $95 million equity financing and expects a $15 million second tranche from its European Investment Bank loan by end-June 2026, totaling $110 million in new capital. The company plans to accelerate U.S. commercialization of its Genio OSA device, citing 40 U.S. sales reps.
4 min readNyxoah SA said it has closed its previously announced underwritten U.S. public offering, selling 55,232,558 ordinary shares at $1.72 (EUR 1.48) each. Gross proceeds are about $95.0 million (EUR 81.9 million). Net proceeds will fund U.S. commercialization, Genio R&D and commercialization, and general corporate purposes; the company also plans to draw EUR 13.8 million from its EIB loan tranche in Q2 2026.
4 min readNyxoah SA (NASDAQ:NYXH) shares rose in Tuesday premarket but are down nearly 70% YTD. The company priced a $95 million underwritten public offering of about 55.2 million shares at $1.72 each, with a 30-day over-allotment option. Proceeds will fund U.S. commercialization and Genio R&D. Nyxoah also began a CEO transition search. In Q1, it reported a 43¢ loss and $7.46M sales; FY2026 sales guidance is $42.16M–$46.84M.
4 min readNyxoah SA (NYXH) reported a loss for the fourth quarter, with revenue falling short of analyst estimates. This indicates a challenging period for the company, as its financial performance did not meet market expectations. Investors will likely be focused on future reports to see how the company plans to address these shortfalls.
2 min readNyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
3 min read
